AbbVie Inc. (ABBV) has been undergoing significant market shifts. The company has been bolstering its
neuropsychiatric portfolio and has completed the acquisition of
Landos Biopharma, enhancing its standing in the inflammatory and autoimmune diseases area. Additionally, an option-to-license agreement to collaborate with
Gilgamesh Pharmaceuticals announced by AbbVie shows progress. Q2
2024 EPS estimates were sadly lowered. The company's
stock has been trending, and despite a recent dip, several analysts deem it to be a valuable pick for
long-term investment. Furthermore, the company beat Q1 earnings and revenue estimates, earning approval for their
Lymphoma drug by the FDA. AbbVie is moving toward compensating for Humira losses, with newer drugs contributing to revenue. Moreover, the company also made strides to expand its biologics manufacturing capacity with a $223 million investment in a Singapore manufacturing site.
Abbvie ABBV News Analytics from Tue, 28 Nov 2023 08:00:00 GMT to Thu, 30 May 2024 15:30:00 GMT -
Rating 4
- Innovation 5
- Information 6
- Rumor -5
